Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.120
+0.110 (10.89%)
At close: Apr 17, 2025, 4:00 PM
1.080
-0.040 (-3.57%)
After-hours: Apr 17, 2025, 5:29 PM EDT
Coherus BioSciences Employees
Coherus BioSciences had 228 employees as of December 31, 2024. The number of employees decreased by 78 or -25.49% compared to the previous year.
Employees
228
Change (1Y)
-78
Growth (1Y)
-25.49%
Revenue / Employee
$1,170,877
Profits / Employee
$125,031
Market Cap
129.80M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
CHRS News
- 2 days ago - Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs - Seeking Alpha
- 4 days ago - Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise - GlobeNewsWire
- 24 days ago - Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 5 weeks ago - Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 - GlobeNewsWire
- 7 weeks ago - Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference - GlobeNewsWire
- 4 months ago - Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 - GlobeNewsWire